Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
Sputnik Light is the first component of Sputnik V
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Govt announces vaccination programme for kids and those above 60 years of age
Subscribe To Our Newsletter & Stay Updated
